Scarica l'app Stockscreener
29.95
1.70%
0.50
Dopo l'orario di chiusura:
30.20
0.25
+0.83%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$29.45
Aprire:
$29.99
Volume 24 ore:
28.76M
Relative Volume:
1.06
Capitalizzazione di mercato:
$170.71B
Reddito:
$63.32B
Utile/perdita netta:
$7.52B
Rapporto P/E:
22.96
EPS:
1.3043
Flusso di cassa netto:
$9.48B
1 W Prestazione:
-1.55%
1M Prestazione:
+4.28%
6M Prestazione:
+14.05%
1 anno Prestazione:
+23.30%
Intervallo 1D:
$29.61
$30.18
Intervallo di 1 settimana:
$29.22
$30.32
Portata 52W:
$23.62
$30.44
Pfizer Inc Stock (PFE) Company Profile
Nome
Pfizer Inc
Settore
Industria
Telefono
(212) 733-2323
Indirizzo
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, MRK, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
29.95 | 170.71B | 63.32B | 7.52B | 9.48B | 1.3043 |
LLY
Lilly Eli Co
|
1,373.70 | 1.22T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
275.20 | 662.49B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
290.79 | 513.86B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
146.33 | 361.02B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
161.10 | 304.26B | 54.66B | 13.58B | 16.05B | 7.0171 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-07-06 | Downgrade | HSBC Securities | Buy → Hold |
| 2026-06-10 | Aggiornamento | RBC Capital Mkts | Underperform → Sector Perform |
| 2026-03-02 | Aggiornamento | Argus | Hold → Buy |
| 2026-02-25 | Iniziato | RBC Capital Mkts | Underperform |
| 2026-02-20 | Iniziato | Barclays | Underweight |
| 2026-02-12 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-02 | Ripresa | Citigroup | Neutral |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-25 | Ripresa | Citigroup | Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-08-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Downgrade | Argus | Buy → Hold |
| 2024-02-23 | Iniziato | Guggenheim | Buy |
| 2024-01-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-10-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-17 | Reiterato | JP Morgan | Neutral |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-06-29 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Downgrade | UBS | Buy → Neutral |
| 2023-01-17 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-12-13 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-04-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-20 | Reiterato | Cowen | Outperform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-13 | Aggiornamento | UBS | Neutral → Buy |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-05-06 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-12-16 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Ripresa | Goldman | Neutral |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-10-12 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-16 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-27 | Aggiornamento | Standpoint Research | Hold → Buy |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-07-30 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Ripresa | Morgan Stanley | Overweight |
| 2019-02-20 | Ripresa | Citigroup | Neutral |
| 2019-01-31 | Aggiornamento | Argus | Hold → Buy |
| 2019-01-31 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Downgrade | UBS | Buy → Neutral |
| 2018-12-11 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Mostra tutto
Pfizer Inc Borsa (PFE) Ultime notizie
GSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth? - Zacks Investment Research
BMY Q3 Earnings Tops Estimates, Higher Charges Weigh on Outlook - Zacks Investment Research
Merck (MRK) Surpasses Q3 Earnings and Revenue Estimates - Zacks Investment Research
Global Dermatological Therapeutics Market to Reach USD 97 Billion by 2034 | DelveInsight - GlobeNewswire Inc.
3 Absurdly Cheap Dividend Stocks to Buy for Under $100 Right Now - The Motley Fool
Buy, Hold or Sell ABBV Stock? Key Tips Ahead of Q3 Earnings - Zacks Investment Research
Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards? - Zacks Investment Research
Pfizer shares may move 3.8% on Nov. 3 earnings release - Investing.com
Pfizer's ELREXFIO meets Phase 3 myeloma endpoint - Mugglehead Investment Magazine
Pfizer posts late-stage trial win for multiple myeloma drug Elrexfio in an earlier line setting - Seeking Alpha
Pfizer’s ELREXFIO Outperforms Standard Regimens and Meets Primary Endpoint in Phase 3 Study in Relapsed or Refractory Multiple Myeloma - Business Wire
Pfizer Inc (PFE) Profile, Company FAQs & Facts, Industry, Sector, Employee Strength - Stocktwits
Pfizer Inc. Receives FDA Expanded Approval for TALZENNA Plus XTANDI for HRR Gene-Mutated Metastatic Androgen Pathway Modulation-Naïve or -Sensitive Prostate Cancer - www.marketscreener.com
Should You Buy, Hold, or Sell BMY Stock Ahead of Q3 Earnings? - Zacks Investment Research
Can Pfizer Stock Get Back To Where It Was? - Trefis
Pfizer Inc. (1PFE.MI) stock price, news, quote and history - Yahoo Finance UK
Pfizer Inc. : Gets a Buy rating from Jefferies - marketscreener.com
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants - Contagion Live
Pfizer Sees Path Forward for Cancer Drug Despite Trial Failure - Bloomberg.com
Pfizer Inc. Advanced Charts | PFE - Barron's
Pfizer details 25‑strain infant vaccine data as pivotal trials advance - Mugglehead Investment Magazine
Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy? - The Motley Fool
Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026 - Business Wire
Micro Pfizer Inc Stock Futures, (XPFE0=F) stock price, news, quote and history - Yahoo Finance UK
Pfizer Inc. (PFE) Company Profile & Facts - Yahoo! Finance Canada
Better Dividend Stock to Buy and Hold: Pfizer or Bristol Myers Squibb? - The Motley Fool
Invesco Pharmaceuticals ETF vs. iShares Biotechnology ETF: Which Is the Better Buy? - The Motley Fool
Micro Pfizer Inc Stock Futures, (XPFE0Z26.CME) Interactive Stock ChartYahoo Finance - Yahoo! Finance Canada
Bristol Myers Squibb vs. Pfizer: Consistency vs. Scale in Revenue - The Motley Fool
Pfizer stock hits 52-week high at 30.26 USD By Investing.com - Investing.com South Africa
Pfizer Inc. Research & Ratings | PFE - Barron's
Pfizer Inc. stock has November 3 call, slightly higher pre-market - AD HOC NEWS
Pfizer announces layoffs at NC facilities, leaving workers and local leaders seeking answers - Yahoo Finance
Pfizer, Inc. (PFE) Stock forecasts - Yahoo Finance UK
Global Oral Drugs Market is Predicted to Surpass USD 1 Trillion Mark by 2034 | DelveInsight - GlobeNewswire Inc.
Pfizer stock: BofA raises target for Pfizer stock to USD 29.00 - AD HOC NEWS
Will Auvelity Continue to Aid Axsome's Top-Line Growth in Q3? - Zacks Investment Research
Can BMY Navigate Generic Challenges Across Its Key Drug Portfolio? - Zacks Investment Research
Bank of America raises target to USD 29 for Pfizer stock - AD HOC NEWS
Forget COVID: Moderna Is Turning Into a Cancer Company -- and Wall Street Is Taking Notice - The Motley Fool
Is Pfizer (NYSE:PFE) Positioned for Renewed Healthcare Sector Attention? - Kalkine Media
Micro Pfizer Inc Stock Futures, (XPFE0H27.CME) stock historical prices and data - Yahoo Finance UK
Lobbying Update: $3,600,000 of PFIZER INC. lobbying was just disclosed - Quiver Quantitative
Pfizer, Inc. (PFE) Stock Forecasts - Yahoo! Finance Canada
Pfizer, Inc. (PFE) Stock Forecasts - Yahoo Finance
Pfizer (PFE) Surpasses Market Returns: Some Facts Worth Knowing - Zacks Investment Research
Ex-White House, Pfizer Execs Squelch Vaccine Skeptic’s Appeal - Bloomberg Law News
GSK's New Drugs and Pipeline Hold the Key to Long-Term Growth - Zacks Investment Research
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It - Zacks Investment Research
Pfizer Inc Azioni (PFE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Pfizer Inc Azioni (PFE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| DAMICO JENNIFER B. | SVP & Controller |
Aug 05 '26 |
Sale |
25.40 |
3,278 |
83,261 |
28,611 |
| BLAYLOCK RONALD E | Director |
Aug 05 '26 |
Buy |
25.46 |
39,231 |
998,821 |
66,938 |
| Buckley Mortimer J | Director |
Aug 05 '26 |
Buy |
25.52 |
37,632 |
960,369 |
37,632 |
| DAMICO JENNIFER B. | SVP & Controller |
Jun 09 '26 |
Sale |
25.70 |
2,000 |
51,400 |
31,397 |
| SAHNI PAYAL | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
56,888 |
1,923,952 |
82,816 |
| LANKLER DOUGLAS M | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
122,907 |
4,156,715 |
282,186 |
| DAMICO JENNIFER B. | SVP & Controller |
Feb 25 '26 |
Option Exercise |
33.82 |
17,558 |
593,812 |
29,744 |
| BOURLA ALBERT | Chairman & CEO |
Feb 25 '26 |
Option Exercise |
33.82 |
491,626 |
16,626,791 |
864,215 |
| Fonseca Lidia | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
56,888 |
1,923,952 |
101,579 |
| McDermott Michael | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
37,925 |
1,282,624 |
114,534 |
2.22%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):